Literature DB >> 32005187

A web application for the design of multi-arm clinical trials.

Michael J Grayling1, James Ms Wason2,3.   

Abstract

BACKGROUND: Multi-arm designs provide an effective means of evaluating several treatments within the same clinical trial. Given the large number of treatments now available for testing in many disease areas, it has been argued that their utilisation should increase. However, for any given clinical trial there are numerous possible multi-arm designs that could be used, and choosing between them can be a difficult task. This task is complicated further by a lack of available easy-to-use software for designing multi-arm trials.
RESULTS: To aid the wider implementation of multi-arm clinical trial designs, we have developed a web application for sample size calculation when using a variety of popular multiple comparison corrections. Furthermore, the application supports sample size calculation to control several varieties of power, as well as the determination of optimised arm-wise allocation ratios. It is built using the Shiny package in the R programming language, is free to access on any device with an internet browser, and requires no programming knowledge to use. It incorporates a variety of features to make it easier to use, including help boxes and warning messages. Using design parameters motivated by a recently completed phase II oncology trial, we demonstrate that the application can effectively determine and evaluate complex multi-arm trial designs.
CONCLUSIONS: The application provides the core information required by statisticians and clinicians to review the operating characteristics of a chosen multi-arm clinical trial design. The range of designs supported by the application is broader than other currently available software solutions. Its primary limitation, particularly from a regulatory agency point of view, is its lack of validation. However, we present an approach to efficiently confirming its results via simulation.

Entities:  

Keywords:  False discovery rate; Familywise error-rate; Multiple comparisons; Optimal design; Power; Sample size

Mesh:

Year:  2020        PMID: 32005187      PMCID: PMC6995188          DOI: 10.1186/s12885-020-6525-0

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  20 in total

1.  Practical guidelines for multiplicity adjustment in clinical trials.

Authors:  M A Proschan; M A Waclawiw
Journal:  Control Clin Trials       Date:  2000-12

2.  Efficacy endpoint selection and multiplicity adjustment methods in clinical trials with inherent multiple endpoint issues.

Authors:  Abdul J Sankoh; Ralph B D'Agostino; Mohammad F Huque
Journal:  Stat Med       Date:  2003-10-30       Impact factor: 2.373

3.  No adjustments are needed for multiple comparisons.

Authors:  K J Rothman
Journal:  Epidemiology       Date:  1990-01       Impact factor: 4.822

4.  Innovation in the pharmaceutical industry: New estimates of R&D costs.

Authors:  Joseph A DiMasi; Henry G Grabowski; Ronald W Hansen
Journal:  J Health Econ       Date:  2016-02-12       Impact factor: 3.883

5.  Reporting of Multi-Arm Parallel-Group Randomized Trials: Extension of the CONSORT 2010 Statement.

Authors:  Edmund Juszczak; Douglas G Altman; Sally Hopewell; Kenneth Schulz
Journal:  JAMA       Date:  2019-04-23       Impact factor: 56.272

6.  More multiarm randomised trials of superiority are needed.

Authors:  Mahesh K B Parmar; James Carpenter; Matthew R Sydes
Journal:  Lancet       Date:  2014-07-26       Impact factor: 79.321

Review 7.  Correcting for multiple-testing in multi-arm trials: is it necessary and is it done?

Authors:  James M S Wason; Lynne Stecher; Adrian P Mander
Journal:  Trials       Date:  2014-09-17       Impact factor: 2.279

Review 8.  Reporting of analyses from randomized controlled trials with multiple arms: a systematic review.

Authors:  Gabriel Baron; Elodie Perrodeau; Isabelle Boutron; Philippe Ravaud
Journal:  BMC Med       Date:  2013-03-27       Impact factor: 8.775

Review 9.  Do multiple outcome measures require p-value adjustment?

Authors:  Ronald J Feise
Journal:  BMC Med Res Methodol       Date:  2002-06-17       Impact factor: 4.615

10.  Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials - an example in hemato-oncology.

Authors:  Louis Jacob; Maria Uvarova; Sandrine Boulet; Inva Begaj; Sylvie Chevret
Journal:  BMC Med Res Methodol       Date:  2016-06-02       Impact factor: 4.615

View more
  2 in total

Review 1.  Systematic review of available software for multi-arm multi-stage and platform clinical trial design.

Authors:  Elias Laurin Meyer; Peter Mesenbrink; Tobias Mielke; Tom Parke; Daniel Evans; Franz König
Journal:  Trials       Date:  2021-03-04       Impact factor: 2.279

2.  Effect of a test-and-treat approach to vitamin D supplementation on risk of all cause acute respiratory tract infection and covid-19: phase 3 randomised controlled trial (CORONAVIT).

Authors:  David A Jolliffe; Hayley Holt; Matthew Greenig; Mohammad Talaei; Natalia Perdek; Paul Pfeffer; Giulia Vivaldi; Sheena Maltby; Jane Symons; Nicola L Barlow; Alexa Normandale; Rajvinder Garcha; Alex G Richter; Sian E Faustini; Christopher Orton; David Ford; Ronan A Lyons; Gwyneth A Davies; Frank Kee; Christopher J Griffiths; John Norrie; Aziz Sheikh; Seif O Shaheen; Clare Relton; Adrian R Martineau
Journal:  BMJ       Date:  2022-09-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.